Genetic Variability of the Monkeypox Virus Clade IIb B.1
Monkeypox is caused by a sylvatic, double-stranded DNA zoonotic virus. Since 1 January 2022, monkeypox cases have been reported to WHO from 106 Member States across six WHO regions, and as of 2 October 2022, a total of 68,900 confirmed cases, including 25 deaths, occurred. Here, by using a whole genome approach, we perform a genetic and phylodynamic survey of the monkeypox virus Clade IIb B.1, which is the lineage causing the current multi-country outbreak. Results suggest that outbreaks seem to be isolated and localized in several epidemic clusters with geographic consistency. Currently, monkeypox appears to be a virus with a flattened genetic variability in terms of evolutionary path, with a very slow rate of growth in the population size. This scenario confirms that the monkeypox virus lacks the evolutionary advantage, given by the high level of mutation rate, which is very strong in RNA viruses. Of course, constant genome-based monitoring must be performed over time in order to detect the change in its genetic composition, if any.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 11(2022), 21 vom: 28. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Scarpa, Fabio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Epidemiology |
|---|
| Anmerkungen: |
Date Revised 28.11.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm11216388 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348761996 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348761996 | ||
| 003 | DE-627 | ||
| 005 | 20231226041019.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm11216388 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1162.xml |
| 035 | |a (DE-627)NLM348761996 | ||
| 035 | |a (NLM)36362616 | ||
| 035 | |a (PII)6388 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Scarpa, Fabio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genetic Variability of the Monkeypox Virus Clade IIb B.1 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.11.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Monkeypox is caused by a sylvatic, double-stranded DNA zoonotic virus. Since 1 January 2022, monkeypox cases have been reported to WHO from 106 Member States across six WHO regions, and as of 2 October 2022, a total of 68,900 confirmed cases, including 25 deaths, occurred. Here, by using a whole genome approach, we perform a genetic and phylodynamic survey of the monkeypox virus Clade IIb B.1, which is the lineage causing the current multi-country outbreak. Results suggest that outbreaks seem to be isolated and localized in several epidemic clusters with geographic consistency. Currently, monkeypox appears to be a virus with a flattened genetic variability in terms of evolutionary path, with a very slow rate of growth in the population size. This scenario confirms that the monkeypox virus lacks the evolutionary advantage, given by the high level of mutation rate, which is very strong in RNA viruses. Of course, constant genome-based monitoring must be performed over time in order to detect the change in its genetic composition, if any | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a genetic diversity | |
| 650 | 4 | |a lineage B.1 | |
| 650 | 4 | |a monkeypox | |
| 650 | 4 | |a orthopoxviruses | |
| 700 | 1 | |a Sanna, Daria |e verfasserin |4 aut | |
| 700 | 1 | |a Azzena, Ilenia |e verfasserin |4 aut | |
| 700 | 1 | |a Cossu, Piero |e verfasserin |4 aut | |
| 700 | 1 | |a Locci, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Angeletti, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Maruotti, Antonello |e verfasserin |4 aut | |
| 700 | 1 | |a Ceccarelli, Giancarlo |e verfasserin |4 aut | |
| 700 | 1 | |a Casu, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Fiori, Pier Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Petrosillo, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Ciccozzi, Massimo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 11(2022), 21 vom: 28. Okt. |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:21 |g day:28 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm11216388 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 21 |b 28 |c 10 | ||